The Common −866G>A Variant in the Promoter of UCP2 Is Associated With Decreased Risk of Coronary Artery Disease in Type 2 Diabetic Men

@article{Cheurfa2008TheC,
  title={The Common −866G>A Variant in the Promoter of UCP2 Is Associated With Decreased Risk of Coronary Artery Disease in Type 2 Diabetic Men},
  author={Nadir Cheurfa and Dani{\`e}le Dubois-Laforgue and Daniela A F Ferrarezi and Andr{\'e} Fernandes Reis and G. M. Brenner and Clara Bouch{\'e} and Claude Le Feuvre and Fr{\'e}d{\'e}ric Fumeron and Jos{\'e} Timsit and Michel Marre and Gilberto Velho},
  journal={Diabetes},
  year={2008},
  volume={57},
  pages={1063 - 1068}
}
OBJECTIVE—Uncoupling protein 2 (UCP2) is a physiological downregulator of reactive oxygen species generation and plays an antiatherogenic role in the vascular wall. A common variant in the UCP2 promoter (−866G>A) modulates mRNA expression, with increased expression associated with the A allele. We investigated association of this variant with coronary artery disease (CAD) in two cohorts of type 2 diabetic subjects. RESEARCH DESIGN AND METHODS—We studied 3,122 subjects from the 6-year… 
The common G-866 A polymorphism of the UCP 2 gene and survival in diabetic patients following myocardial infarction
TLDR
Diabetic patients in this post-myocardial infarction cohort with UCP2 -866 AA/GA genotype have poorer survival and higher myeloperoxidase levels than their GG counterparts, and this phenomenon was confined to male patients.
The common G-866A polymorphism of the UCP2 gene and survival in diabetic patients following myocardial infarction
TLDR
Diabetic patients in this post-myocardial infarction cohort with UCP2 -866 AA/GA genotype have poorer survival and higher myeloperoxidase levels than their GG counterparts, and the interaction of diabetes with genotype was significantly predictive of survival.
Association between UCP2 A55V polymorphism and risk of cardiovascular events in patients with multi-vessel coronary arterial disease
TLDR
The hypothesis that A55V polymorphism is associated with UCP2 functional alterations that increase the risk of cardiovascular events in patients with previous coronary artery disease and dysglycemia is supported.
Interaction between the UCP2 -866 G>A polymorphism, diabetes, and β-blocker use among patients with acute coronary syndromes
TLDR
A significant interaction between -866G>A and β-blocker response among ACS patients with diabetes was identified and conferred greater gene transcriptional activity than -866A in cell lines and in obese patients, which may help gain insight into the mechanisms underlying the beneficial and detrimental effects ofβ-blockers in those with diabetes.
The C allele of the reactive oxygen species modulator 1 (ROMO1) polymorphism rs6060566 is a biomarker predicting coronary artery stenosis in Slovenian subjects with type 2 diabetes mellitus
TLDR
The rs6060566 polymorphism of the ROMO1 gene is not a risk factor for MI in Caucasians with type 2 diabetes, however, it is found that subjects carrying the C allele were at a 3.27-fold increased risk of developing severe CAD compared with those who had non-obstructive CAD.
The UCP2 -866G/A, Ala55Val and UCP3 -55C/T polymorphisms are associated with premature coronary artery disease and cardiovascular risk factors in Mexican population
TLDR
The results suggest the association of the UCP2 -866 (rs659366) polymorphism with risk of developing pCAD.
Variation in the UCP2 and UCP3 genes associates with abdominal obesity and serum lipids: The Finnish Diabetes Prevention Study
TLDR
Genetic variation in the UCP2-UCP3 gene cluster may act as a modifier increasing serum lipid levels and indices of abdominal obesity, and may thereby also contribute to the metabolic aberrations observed in obesity and type 2 diabetes.
The role of uncoupling protein 2 (UCP2) on the development of type 2 diabetes mellitus and its chronic complications.
TLDR
Uncoupling protein 2 (UCP2) is expressed in several tissues, and acts in the protection against oxidative stress; in the negative regulation of insulin secretion by beta cells, and in fatty acid metabolism, which are associated with DM2 pathogenesis and its chronic complications.
Genetic Variance in Uncoupling Protein 2 in Relation to Obesity, Type 2 Diabetes, and Related Metabolic Traits: Focus on the Functional −866G>A Promoter Variant (rs659366)
TLDR
Current evidence of association of UCP2 genetic variation with obesity and type 2 diabetes, with focus on the −866G>A polymorphism is summarized.
Association of uncoupling protein (Ucp) gene polymorphisms with cardiometabolic diseases
The hereditary aspect of obesity is a major focus of modern medical genetics. The genetic background is known to determine a higher-than-average prevalence of obesity in certain regions, like
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion.
The onset of type 2 diabetes (T2DM) is preceded by obesity, insulin resistance, and impaired beta-cell function. Uncoupling protein-2 (UCP2) is a widely expressed inner mitochondrial membrane
A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans.
TLDR
It is shown that the pancreatic transcription factor PAX6 preferentially binds to and more effectively trans activates the variant than the wild-type UCP2 promoter allele in the beta-cell line INS1-E, which affords relative protection against type 2 diabetes.
A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans
TLDR
It is shown that a common G/A polymorphism in the UCP2 promoter region is associated with enhanced adipose tissue mRNA expression in vivo and results in increased transcription of a reporter gene in the human adipocyte cell line PAZ-6.
A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects.
TLDR
Results indicate that the common -866G/A polymorphism in the UCP2 gene may contribute to the biological variation of insulin secretion in humans.
The common -866 G/A polymorphism in the promoter of uncoupling protein 2 is associated with increased carbohydrate and decreased lipid oxidation in juvenile obesity.
TLDR
Metabolic studies in 147 juvenile obese subjects showed that homozygosity for the UCP2 promoter variant A was associated with important changes in energy metabolism compared with other genotypes, suggesting a role for U CP2 in the partitioning of metabolic fuels.
The effects of the overexpression of recombinant uncoupling protein 2 on proliferation, migration and plasminogen activator inhibitor 1 expression in human vascular smooth muscle cells
TLDR
The present study demonstrates that UCP-2 can modify atherosclerotic processes in HVSMCs in response to high glucose and Ang II, and suggests that agents increasing U CP-2 expression in vascular cells may help prevent the development and progression of atherosclerosis in patients with diabetes and hypertension.
Protective Role of Uncoupling Protein 2 in Atherosclerosis
TLDR
A protective role for UCP2 against atherosclerosis is suggested, with a marked increase in atherosclerotic lesion size in the thoracic aorta and a significant increase in plaque composition, which suggests enhanced oxidative stress.
...
1
2
3
4
...